POM-V Prescription Required

Aivlosin 42.5 mg/g Oral Powder for Pigs

Active ingredient: Tylvalosin

Form

Powder

Species

Pigs

Manufacturer

Eco Animal Health Ltd

VMD MA No.

13277/5001

View official SPC (PDF)

Prices coming soon

We're adding pharmacy price data for this medication.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed pharmacy.

Clinical information

Aivlosin 42.5 mg/g Oral Powder for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

•
susceptible strains of Mycoplasma hyopneumoniae in pigs. At the
recommended dose, lung lesions and weight loss are reduced but infection
with Mycoplasma hyopneumoniae
•Lawsonia
intracellularis in herds where there is a diagnosis based on clinical history,
post-mortem findings and clinical pathology results.
•Brachyspira
hyodysenteriae in herds where the disease has been diagnosed.

None

Pigs.

Issued: December 2024
AN: 02144/2023
None known.
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local
representative or the national competent authority via the national reporting
system. See also section 16 of the package leaflet for contact details.

Acute cases and severely diseased pigs with reduced food or water intake
should be treated with a suitable injectable product.

Issued: December 2024
AN: 02144/2023
Generally, strains of have higher minimal inhibitory
concentration (MIC) values in cases of resistance against other macrolides,
such as tylosin. The clinical relevance of this reduced susceptibility is not fully
explored. Cross-resistance between tylvalosin and other macrolides cannot be
excluded.

Special precautions for use in animals
It is sound clinical practice to base treatment on susceptibility testing of the
bacteria isolated from the animal. If this is not possible, therapy should be
based on local (regional, farm level) epidemiological information about
susceptibility of target bacteria.
Use of the veterinary medicinal product deviating from the instructions in the
SPC may increase the risk of development and selection of resistant bacteria
and decrease the effectiveness of treatment with other macrolides due to the
potential for cross-resistance.
Good management and hygiene practices should be followed to reduce the risk
of re-infection.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Tylvalosin has been shown to cause hypersensitivity (allergic) reactions in
laboratory animals; therefore, people with known hypersensitivity to tylvalosin
should avoid contact with this product.
When mixing the veterinary medicinal product and handling the medicated
premix, direct contact with eyes, skin and mucous membranes should be
avoided. Personal protective equipment consisting of impervious gloves and a
half-mask respirator conforming to European Standard EN 149 or a non-
disposable respirator conforming to European Standard EN 140 with a filter
conforming to European Standard EN 143 should be worn when mixing the
product. Wash contaminated skin.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.

None known.

Store below 30 °C.
Keep the container tightly closed.
Store in the original container.

Meat and offal: 2 days.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.